Xiao Shan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiao Shan has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Yanzhao Zhou
Department of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
3 shared publicationsZemin Ji
Department of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
3 shared publicationsBaochen Wang
Department of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
2 shared publicationsHongyuan Dong
Tianjin Institute of Immunology, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
2 shared publicationsPenghui Hu
Department of Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China; Tianjin Institute of Immunology, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
2 shared publications- Qiujing Yu
University of Electronic Science and Technology of China
2 shared publications
Latest Publications
- Open Access
- 30 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110658
Phosphoglycerate dehydrogenase interacts with and inhibits the protein kinase TAK1 to mitigate septic shock
- 30 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110658
Open AccessPhosphoglycerate dehydrogenase interacts with and inhibits the protein kinase TAK1 to mitigate septic shock
- Open Access
- 31 October 2024
- Published by Elsevier in Redox Biology
- Vol. 78, 103413
Riboflavin kinase binds and activates inducible nitric oxide synthase to reprogram macrophage polarization
- 31 October 2024
- Published by Elsevier in Redox Biology
- Vol. 78, 103413
Open AccessRiboflavin kinase binds and activates inducible nitric oxide synthase to reprogram macrophage polarization
- Top Cited PapersOpen Access
- 11 May 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Gallbladder cancer: current and future treatment options
Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical effect. However, most patients have already been at the locally advanced stage or the tumor has metastasized at the initial diagnosis. The postoperative recurrence rate and 5-year survival rate remain unsatisfactory even after radical resection for gallbladder cancer. Hence, there is an urgent need for more treatment options, such as neoadjuvant therapy, postoperative adjuvant therapy and first-line and second-line treatments of local progression and metastasis, in the whole-course treatment management of gallbladder cancer patients. In recent years, the application of molecular targeted drugs and immunotherapy has brought greater hope and broader prospects for the treatment of gallbladder cancer, but their effects in improving the prognosis of patients still lack sufficient evidence-based medicine evidence, so many problems should be addressed by further research. Based on the latest progress in gallbladder cancer research, this review systematically analyzes the treatment trends of gallbladder cancer.
- 11 May 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Top Cited PapersOpen AccessGallbladder cancer: current and future treatment options
Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical effect. However, most patients have already been at the locally advanced stage or the tumor has metastasized at the initial diagnosis. The postoperative recurrence rate and 5-year survival rate remain unsatisfactory even after radical resection for gallbladder cancer. Hence, there is an urgent need for more treatment options, such as neoadjuvant therapy, postoperative adjuvant therapy and first-line and second-line treatments of local progression and metastasis, in the whole-course treatment management of gallbladder cancer patients. In recent years, the application of molecular targeted drugs and immunotherapy has brought greater hope and broader prospects for the treatment of gallbladder cancer, but their effects in improving the prognosis of patients still lack sufficient evidence-based medicine evidence, so many problems should be addressed by further research. Based on the latest progress in gallbladder cancer research, this review systematically analyzes the treatment trends of gallbladder cancer.